Needham Maintains Buy on Heron Therapeutics, Raises Price Target to $5
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Serge Belanger has maintained a Buy rating on Heron Therapeutics (NASDAQ:HRTX) and increased the price target from $4 to $5.
March 13, 2024 | 10:28 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst Serge Belanger maintains a Buy rating on Heron Therapeutics and raises the price target from $4 to $5.
The increase in price target by a reputable analyst firm like Needham typically signals a positive outlook on the stock, suggesting potential upside. This can lead to increased investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100